Skip to main content
logo
Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
10.33
+0.09 (0.88%)
At close: Aug 1, 2025, 4:00 PM
10.29
-0.04 (-0.39%)
After-hours: Aug 1, 2025, 7:16 PM EDT

Adaptive Biotechnologies Revenue by Segment

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
MRD
156.62M145.53M136.14M123.34M113.94M102.74M100.08M95.37M
MRD Growth
37.46%41.65%36.03%29.33%25.53%17.90%32.40%33.39%
Immune Medicine
32.90M33.43M41.14M45.43M60.56M67.54M79.61M94.23M
Immune Medicine Growth
-45.67%-50.50%-48.32%-51.79%-35.27%-31.20%-13.89%6.86%

Immune Medicine Revenue Breakdown

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Immune Medicine Service
20.54M19.98M23.27M23.06M22.42M24.96M28.66M29.98M
Immune Medicine Service Growth
-8.37%-19.96%-18.79%-23.09%-29.43%-21.46%2.98%1.83%
Collaboration
12.36M13.45M17.87M22.37M38.15M42.58M50.95M64.26M
Collaboration Growth
-67.59%-68.41%-64.93%-65.19%-38.27%-35.86%-21.15%9.38%

Adjusted EBITDA by Segment

Period EndingMar 31, 2025Dec 31, 2024
Immune
-24.52M-26.01M
MRD
-28.08M-41.22M

Operating Metrics

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Number of Clonoseq Tests Delivered
82.18K76.11K70.84K66.31K61.46K56.50K51.34K45.92K
Number of Clonoseq Tests Delivered Growth
33.72%34.71%37.98%44.41%48.98%53.23%54.67%53.64%

MRD Revenue Breakdown

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Service
144.12M133.03M123.64M115.84M109.44M102.74M98.08M93.37M
Service Growth
31.69%29.48%26.06%24.07%24.69%26.61%37.00%41.48%
Regulatory Milestone
12.50M-12.50M7.50M4.50M---
Regulatory Milestone Growth
177.78%-------
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.